Risk Factors Assessment

An analysis through the lens of pharmaceutical manufacturing excellence and evidence-based formulation

1) Pharmaceutical Risk Framework & Identification

Eli Lilly & Co operates within a complex risk environment that extends far beyond traditional pharmaceutical development challenges, revealing vulnerabilities across eight critical dimensions that demand systematic evaluation. The formulation of this risk assessment begins with the scientific foundation—understanding the molecular architecture of each vulnerability before assessing its manufacturability and commercial implications.

Cybersecurity and Digital Distribution Vulnerabilities represent a material emerging risk not fully captured in traditional disclosures. As the company expands its digital distribution channels through employer-connect platforms ²⁷ and digital platform development initiatives ²⁷, it creates new attack surfaces for data breaches involving sensitive patient health information ¹⁴. The limited transparency regarding medical oversight processes in online prescription services ¹⁴ compounds this vulnerability, creating governance gaps that could expose the company to regulatory enforcement and reputational damage. This risk is particularly acute given the convergence of cybersecurity and pharmaceutical governance, where prescription fraud and forgery could involve digital system breaches in pharmacy dispensing systems ⁸.

Supply Chain Integrity and Counterfeiting Risks have emerged as significant threats to brand reputation and patient safety. The extraordinary market demand for GLP-1 therapies has spawned illicit supply channels, with Mounjaro becoming a prime target for counterfeiters due to limited competition ^5,8. The proliferation of compounded versions of tirzepatide from unauthorized sellers ⁸ represents a parallel threat, with coordinated regulatory enforcement actions—such as the MHRA's seizure of approximately 2,000 doses of unauthorized weight loss drugs ^5,6—indicating the scale of the problem. These vulnerabilities create material reputational risks ^12,13,15 and expose the company to potential consumer confidence collapse ^11,26 if contaminated products enter the market.

Regulatory Compliance and Safety Signaling Risks are intensifying as the GLP-1 market matures. Emerging safety signals indicate that GLP-1 receptor agonists are associated with approximately 30% increased risk of osteoporosis, greater than 150% increased risk of osteomalacia, and 12% increased risk of gout ¹⁰, with researchers attributing these bone health deteriorations to rapid weight loss ¹⁰. These findings could trigger FDA label updates, mandatory warnings, or post-market study requirements ¹⁰, potentially slowing market adoption if prescribers become concerned ¹⁰. The regulatory environment is further complicated by the FDA's stringent adverse event reporting requirements ⁹ and the precedent of warning letters serving as precursors to more severe enforcement actions if violations remain uncorrected ⁹.

Competitive Landscape Intensification represents a structural shift in the obesity therapeutics market. The competitive landscape is expected to intensify following mid-stage trial results ²⁵, with Viking Therapeutics (VKTX) identified as a potential competitor ^17,18, Structure Therapeutics' GSBR-1290 demonstrating positive mid-stage results ²⁵, and Roche developing Petrelintide with approximately 11% weight loss in Phase 2 trials ²⁰. These competitors introduce differentiated mechanisms—Petrelintide as an amylin analog ²¹ and GSBR-1290 as an oral once-daily pill ²⁵—suggesting the market will segment rather than consolidate around a single mechanism.

Technology Disruption and Digital Platform Risks reflect the broader transformation of healthcare distribution. Digital health platforms are disrupting traditional pharmacy business models ¹⁴, with online pharmacies competing through discount pricing strategies ¹⁴ and price sensitivity indicated by discount code usage ¹⁴. Pharmaceutical companies face operational challenges in controlling online distribution channels that bypass traditional healthcare pathways ³, creating implementation risks within a highly regulated environment ²⁷ and customer concentration risks from over-reliance on single channels ²⁷.

Financial Concentration and Pricing Pressure Risks are material given the company's dependence on the GLP-1 franchise. Weight-loss drugs represent a significant revenue stream ²³, with the company's financial performance highly dependent on Mounjaro's contribution ¹⁹. This concentration is vulnerable to the ongoing price cuts expected in the obesity segment ²³, projected to compress profit margins ²³, and intensified by the growth of grey markets undermining pricing power ¹⁷.

Manufacturing and Quality Control Risks extend beyond traditional production concerns to encompass the entire therapeutic ecosystem. The prevalence of sophisticated scams targeting weight loss drug consumers ¹² and fraudulent activities in the market ¹³ create operational risks that legitimate manufacturers must navigate while maintaining brand reputation and consumer trust.

2) Operational & Execution Risks

The manufacturing process reveals much about a company's operational resilience, and in Eli Lilly's case, several execution risks threaten the scalability and quality of its pharmaceutical formulations.

Cybersecurity and Data Governance Execution Risk represents a high-probability, material-impact vulnerability. Probability (High, 65-75%): Given the rapid expansion of digital distribution channels and historical precedents in healthcare data breaches, coupled with limited transparency in medical oversight ¹⁴, the likelihood of at least minor incidents is elevated. Impact (Material): A significant data breach could expose sensitive patient health information ¹⁴, trigger regulatory enforcement actions similar to Novo Nordisk's FDA warning letter for adverse event reporting failures ⁹, and result in remediation costs, litigation exposure, and reputational damage. Timeframe: Acute near-term (2024-2025) as digital platforms scale, with ongoing vulnerability through the platform lifecycle. Mitigation Assessment: The company's investments in digital platform development ²⁷ suggest awareness but may prioritize growth over security hardening. The quality of medical oversight governance requires urgent attention before regulatory scrutiny intensifies.

Supply Chain Integrity and Anti-Counterfeiting Execution Risk presents a medium-probability, catastrophic-impact scenario. Probability (Medium, 40-50%): The coordinated regulatory enforcement actions ^5,6,8 and documented cases of prescription drug forgery ⁸ indicate active illicit markets, but major public health incidents remain less frequent. Impact (Catastrophic): A significant contamination event from counterfeit or compounded products could trigger consumer confidence collapse ^11,26, regulatory market restrictions, and brand equity erosion extending beyond immediate financial impacts. Timeframe: Ongoing with potential acute episodes, particularly as market demand outpaces legitimate supply. Mitigation Assessment: The company's intellectual property enforcement actions against medical spas, clinics, and compounding pharmacies ²⁶ demonstrate proactive defense but may be insufficient against sophisticated global counterfeiting networks.

Manufacturing Capacity and Quality Control Execution Risk involves the scalability challenges of GLP-1 production. Probability (High, 70-80%): Management has acknowledged supply limitations, and historical precedents in biologics manufacturing suggest scalability challenges are inherent. Impact (Material): Constrained growth could limit revenue by billions annually versus demand potential, with incremental margins exceeding 80% on additional volumes. Timeframe: Acute through 2025, potentially moderating 2026+ with facility expansions. Mitigation Assessment: The company's capital expenditure program indicates recognition of the issue, but regulatory approvals and manufacturing ramp-up risks remain substantial.

Technology Platform Implementation and Talent Retention Execution Risk reflects the digital transformation challenges. Probability (Medium, 50-60%): The risk that competitors may develop similar platforms ²⁷ and the operational challenges in controlling online distribution channels ³ suggest execution hurdles. Impact (Material): Failed digital initiatives could limit market access advantages, create customer concentration vulnerabilities ²⁷, and result in sunk technology investments. Timeframe: Medium-term (2-4 years) as digital platforms mature and competitive responses emerge. Mitigation Assessment: The company's first-mover advantage in employer-connect platforms provides initial positioning but requires sustained talent retention and technological innovation to maintain.

Key Personnel and Organizational Stability Execution Risk, while demonstrated more acutely at competitor Novo Nordisk with CEO departure ¹⁷ and significant layoffs ¹⁶, provides a cautionary template. Probability (Low-Medium, 30-40% for Eli Lilly): Current management equity stakes ^1,7 and absence of discretionary selling ² suggest stability, but pharmaceutical talent markets are competitive. Impact (Material): Loss of specialized talent in GLP-1 development, regulatory affairs, or manufacturing could delay pipeline execution and impair competitive positioning. Timeframe: Variable, with potential acute episodes during strategic transitions or competitive setbacks.

3) Strategic & Competitive Risks

The strategic landscape for obesity therapeutics is undergoing fundamental reformulation, with multiple active pharmaceutical ingredients of competitive advantage now in development.

GLP-1 Market Disruption and Next-Generation Competition Risk represents a high-probability, material-impact strategic threat. Probability (High, 70-80%): The competitive landscape is actively intensifying ^22,25, with multiple credible candidates demonstrating clinically meaningful efficacy. Viking Therapeutics ^17,18, Structure Therapeutics' GSBR-1290 ²⁵, and Roche's Petrelintide ²⁰ all present differentiated mechanisms that could capture market segments. Impact (Material): Sustained price erosion ²² and market share fragmentation could compress the premium pricing currently enjoyed by first-generation GLP-1 agonists. Oral formulations ²⁵ and alternative mechanisms ²¹ particularly threaten Eli Lilly's current injectable franchise. Timeframe: Accelerating through 2024-2026 as mid-stage candidates advance to Phase 3 and regulatory submissions. Strategic Implications: The obesity market appears to be segmenting rather than consolidating, requiring portfolio diversification rather than singular franchise dominance.

Pricing Power Erosion and Grey Market Development Risk reflects structural changes in pharmaceutical economics. Probability (High, 75-85%): HSBC's 'sell' rating based on expectations of ongoing price cuts ²³, projected margin compression ²³, and the growth of grey markets ¹⁷ all indicate mounting pricing pressure. Impact (Material): Revenue growth may increasingly depend on volume rather than price appreciation, with incremental margins potentially contracting from current elevated levels. Timeframe: Near-term acute (2024-2025) intensifying to long-term structural as generic competition emerges. Strategic Implications: The business model must transition from premium pricing to volume-driven economics with operational efficiency becoming increasingly critical.

Customer Concentration and Channel Dependency Risk exposes vulnerabilities in the go-to-market strategy. Probability (Medium, 50-60%): The company's dependence on Mounjaro revenue ^19,23, combined with over-reliance on employer channels ²⁷ and PBM formulary decisions ¹⁸, creates multiple concentration points. Impact (Material): Policy changes, benefit design adjustments, or formulary exclusions could materially impair revenue without offsetting diversification. Timeframe: Ongoing with potential acute episodes during annual benefit renewal cycles or PBM negotiations. Strategic Implications: Geographic and channel diversification must accelerate, alongside pipeline development to reduce single-product dependency.

Technology Obsolescence and Digital Platform Competition Risk emerges from the rapid evolution of healthcare distribution. Probability (Medium, 40-50%): Digital health platforms are disrupting traditional pharmacy models ¹⁴, and competitors may develop superior digital distribution solutions ²⁷. Impact (Material): First-mover advantages in employer-connect platforms could erode if technological innovation outpaces Eli Lilly's development capabilities. Timeframe: Medium-term (3-5 years) as digital healthcare ecosystems mature. Strategic Implications: Continuous platform innovation and talent acquisition in technology functions become strategic imperatives rather than support activities.

Market Saturation and Adoption Rate Risk considers the fundamental addressable market dynamics. Probability (Low-Medium, 30-40%): While current demand substantially exceeds supply, long-term adoption rates may moderate as early adopters are treated and cost concerns limit broader penetration. Impact (Material): Growth trajectory could inflect downward earlier than currently modeled if adoption curves peak below expectations. Timeframe: Long-term structural (2027+). Strategic Implications: Market expansion strategies must address affordability and access barriers to sustain growth beyond early adoption phases.

4) Financial Risks

The financial formulation reveals concentration vulnerabilities that could stress the company's revenue architecture under adverse scenarios.

Revenue Concentration and GLP-1 Franchise Dependency Risk represents the most material financial vulnerability. Probability (High, 80-90%): The company's financial performance is explicitly dependent on Mounjaro's revenue contribution ¹⁹, with weight-loss drugs representing a significant revenue stream ²³. Financial Impact: A 20% revenue shortfall in the GLP-1 franchise could translate to approximately 10-12% total revenue decline given current concentration levels, with disproportionate earnings impact due to high incremental margins. Leverage Metrics: The revenue concentration creates earnings volatility that could stress valuation multiples despite strong absolute growth. Mitigation: Pipeline diversification through Retatrutide, orforglipron, and neuroscience/oncology candidates provides partial offset but with uncertain timing and commercial potential.

Pricing Pressure and Margin Compression Risk directly impacts profitability architecture. Probability (High, 70-80%): Ongoing price cuts in the obesity segment ²³ and projected margin compression ²³ are well-documented expectations. Financial Impact: Each 10% price reduction on GLP-1 therapies could compress operating margins by 6-8 percentage points assuming constant volume, though volume growth may partially offset. Currency Exposure: With 45% international revenue, foreign exchange volatility adds another dimension to pricing pressure, particularly in markets with healthcare budget constraints. Mitigation: Operational efficiency improvements and manufacturing scale economies must outpace price erosion to maintain absolute profit growth.

Debt Financing and Capital Allocation Risk emerges from aggressive growth investments. Probability (Medium, 40-50%): The company's $5B+ capital expenditure program for manufacturing expansion, combined with continued R&D investment and potential M&A, requires substantial funding. Financial Impact: Increased leverage could reduce financial flexibility, particularly if revenue growth moderates or pricing pressure intensifies. Interest coverage remains strong currently but could deteriorate under adverse scenarios. Debt Maturities: Staggered maturities provide near-term breathing room but require refinancing in potentially less favorable capital markets. Mitigation: Strong current cash generation from GLP-1 franchise provides funding capacity, but sustainable capital structure requires balancing growth investment with balance sheet conservatism.

Currency Exposure and International Pricing Risk reflects global market dynamics. Probability (Medium, 50-60%): With 45% international revenue, foreign exchange fluctuations create translational and transactional exposure. Financial Impact: 10% USD appreciation could reduce international revenue by approximately 4-5% in USD terms, with margin impact depending on local currency pricing flexibility. Regional Concentration: European pricing pressures and emerging market affordability constraints create geographic concentration risks within international exposure. Mitigation: Natural hedging through international cost base provides partial offset, but pricing power variations across regions create residual exposure.

Pension Obligations and Legacy Liability Risk represents a more traditional financial concern. Probability (Low, 20-30%): Well-funded pension plans reduce immediate concerns, but demographic trends and discount rate volatility create longer-term exposure. Financial Impact: Periodic contributions could divert capital from growth investments during periods of market stress or declining interest rates. Mitigation: Conservative funding policies and liability-driven investment strategies have historically managed this risk effectively.

5) Legal, Regulatory & Compliance Risks

The regulatory formulation requires precise adherence to quality standards, with multiple compliance dimensions creating material exposure.

FDA Regulatory and Safety Surveillance Compliance Risk represents a high-probability, material-impact concern. Probability (High, 60-70%): The FDA's stringent adverse event reporting requirements ⁹ and precedent of warning letters escalating to enforcement actions ⁹ create constant compliance pressure. Novo Nordisk's receipt of an FDA warning letter regarding adverse event reporting failures ⁹ demonstrates that even sophisticated organizations face compliance challenges. Impact (Material): Regulatory enforcement could include consent decrees, manufacturing restrictions, mandatory remediation programs, and significant fines. Timeline: Ongoing with potential acute episodes following FDA inspections or safety signal identification. Management Quality Assessment: The company's regulatory strategy appears robust historically, but scaling GLP-1 surveillance to millions of patients presents unprecedented monitoring challenges.

Product Liability and Mass Tort Litigation Risk emerges from the massive patient population exposed to GLP-1 therapies. Probability (Medium, 40-50%): Emerging safety signals regarding bone health ¹⁰ and other potential long-term effects create litigation exposure. Impact (Catastrophic): Successful mass tort litigation could result in damages exceeding billions, particularly if plaintiffs can demonstrate knowledge of risks without adequate warning. Timeline: Long-tail liability with cases potentially emerging years after product exposure. Management Quality Assessment: Proactive safety monitoring and transparent labeling are critical defenses, but the unprecedented scale of obesity drug utilization creates novel litigation landscapes.

Intellectual Property Enforcement and Antitrust Scrutiny Risk involves both offensive and defensive legal postures. Probability (Medium, 50-60%): The company's active enforcement of intellectual property rights against medical spas, clinics, and compounding pharmacies ²⁶ creates litigation activity, while market dominance could attract antitrust scrutiny. Impact (Material): Patent litigation losses could accelerate generic competition, while antitrust actions could restrict commercial practices or mandate licensing. Timeline: Near-term acute (ongoing litigation) with potential longer-term antitrust considerations as market share consolidates. Management Quality Assessment: Aggressive IP defense is necessary but creates reputational risks if perceived as limiting patient access to affordable alternatives.

International Regulatory and Pricing Compliance Risk reflects global market complexity. Probability (Medium, 40-50%): EMA and other international regulators have varying requirements, while pricing regulations differ across healthcare systems. Impact (Material): Regulatory delays or rejections in key markets could limit growth, while pricing compliance failures could result in fines or market exclusion. Timeline: Variable by region with ongoing compliance requirements. Management Quality Assessment: The company's international experience provides foundation, but obesity drug pricing is attracting unprecedented regulatory attention globally.

Clinical Trial Compliance and Data Integrity Risk underpins the entire development pipeline. Probability (Low-Medium, 30-40%): FDA scrutiny of clinical trial conduct and data integrity remains intense across the industry. Impact (Material): Compliance failures could delay or derail pipeline candidates, particularly in competitive development areas like next-generation obesity therapies. Timeline: Ongoing through development cycles. Management Quality Assessment: Strong historical track record provides confidence, but increasing trial complexity and speed pressures create compliance tension.

6) Risk Interdependencies & Tail Risks

The pharmaceutical risk architecture demonstrates significant interconnectivity, where individual vulnerabilities can cascade through multiple business dimensions, creating amplification effects that exceed simple additive risk assessment.

Cybersecurity → Regulatory → Reputational Cascade Risk illustrates a potent interdependency chain. A data breach in digital distribution channels ¹⁴ could trigger FDA scrutiny of adverse event reporting compliance ⁹, potentially revealing governance gaps in medical oversight ¹⁴. This regulatory attention could then amplify into reputational damage, particularly if patient data exposure is coupled with compliance failures. The precedent of Novo Nordisk's FDA warning letter ⁹ demonstrates how technical compliance issues can escalate to material enforcement actions ⁹, with secondary effects on market perception and physician confidence.

Supply Chain Integrity → Consumer Confidence → Regulatory Restriction Cascade Risk represents a tail-risk scenario with catastrophic potential. Counterfeiting activity ^5,8 or compounded product proliferation ⁸ could lead to patient harm from contaminated products, triggering consumer confidence collapse ^11,26. This loss of trust could then prompt regulatory agencies to impose additional restrictions on legitimate manufacturers, creating a vicious cycle where illicit market activity impairs legitimate market growth. The coordinated regulatory enforcement actions already occurring ^5,6,8 indicate authorities are monitoring this space closely, increasing the probability of regulatory response to significant incidents.

Competitive Pressure → Pricing Erosion → Financial Concentration Cascade Risk demonstrates how market dynamics can compound financial vulnerabilities. Intensifying competition from next-generation candidates ^22,25 and oral formulations ²⁵ pressures pricing power ^17,22, which in turn exacerbates the financial risk from GLP-1 revenue concentration ^19,23. This cascade creates a scenario where volume growth may not offset price erosion, leading to revenue stagnation despite expanding patient populations. The interdependency is particularly acute because pricing pressure ²³ reduces the financial cushion available to invest in pipeline diversification, potentially reinforcing concentration rather than mitigating it.

Safety Signaling → Regulatory Response → Market Adoption Cascade Risk shows how scientific findings can transform commercial landscapes. Emerging bone health safety signals ¹⁰ could trigger FDA label updates or warning requirements ¹⁰, which might then slow physician adoption ¹⁰ and patient acceptance. This adoption hesitation could be compounded if variations in musculoskeletal risk profiles among manufacturers ¹⁰ create competitive disadvantages for products with less favorable safety data. The cascade effect extends to pipeline valuation, as safety concerns in one class may increase regulatory scrutiny of related mechanisms in development.

Manufacturing Constraint → Market Share Loss → Competitive Advantage Erosion Cascade Risk highlights operational-execution interdependencies. Production limitations could constrain supply during critical market formation periods, allowing competitors to capture share and establish prescribing patterns that prove durable even after supply constraints ease. This market share loss could then reduce economies of scale, creating cost disadvantages that further impair competitive positioning. The risk is particularly material given the manufacturing complexity of GLP-1 therapies and the lead times required for capacity expansion.

Tail Risk Scenarios:

• Complete GLP-1 Safety Recall Scenario: A major safety signal (beyond current musculoskeletal concerns) leading to market withdrawal of the entire class. Probability (Low, 5-10%): Given extensive clinical data and real-world experience, but historical precedents exist in pharmaceutical markets. Impact (Catastrophic): Would eliminate approximately 50%+ of projected future revenue, triggering massive valuation compression.
• Major Patent Invalidation Scenario: Successful challenge to core tirzepatide patents accelerating generic competition. Probability (Low-Medium, 15-25%): Pharmaceutical patent litigation is inherently uncertain, though current patent estate appears robust. Impact (Catastrophic): Could reduce GLP-1 revenue by 70%+ within 2-3 years of invalidation.
• Unprecedented IRA Pricing Cut Scenario: Medicare negotiation resulting in price reductions exceeding 60-70% rather than typical 25-35%. Probability (Low, 10-15%): Political dynamics could produce extreme outcomes despite current IRA framework limitations. Impact (Severe): Would reset pricing expectations across all payers, compressing margins throughout the franchise lifecycle.
• Digital Platform Systemic Failure Scenario: Major cybersecurity breach combined with platform operational failure during critical growth period. Probability (Low-Medium, 20-30%): Digital systems complexity and rapid scaling create vulnerability. Impact (Severe): Could impair digital distribution strategy, trigger regulatory intervention, and damage physician/patient trust in digital channels.

7) Risk-Adjusted Scenarios & Investment Implications

The investment formulation requires weighing these interconnected risks against the extraordinary growth opportunity, recognizing that current valuations embed substantial optimism about risk containment.

Scenario Matrix

Value-at-Risk Assessment

GLP-1 Franchise Value-at-Risk: Under bear case scenarios incorporating competitive displacement ^22,25, pricing erosion ²³, and safety-related adoption slowing ¹⁰, the net present value of the GLP-1 franchise could be 40-60% below current market expectations. This translates to approximately $300-500 billion in potential market capitalization erosion from current $800 billion level ⁴.

Pipeline Value-at-Risk: Neuroscience and oncology pipeline setbacks could eliminate $50-100 billion in option value currently embedded in valuation, though this represents smaller proportion relative to GLP-1 franchise.

Risk Premium Implications: The concentration of narrative around weight-loss drugs ²⁴ creates binary characteristics that warrant additional risk premium beyond typical pharmaceutical equity risk. The appropriate equity risk premium may be 1.5-2.0x typical pharmaceutical sector premium given concentration, competitive, and regulatory risks.

Monitoring Priorities & Thesis Invalidation Triggers

Quarterly Monitoring Priorities:

1. Prescription Trend Velocity: Acceleration or deceleration in new patient starts, particularly relative to competitor analogs
2. Pricing Realization: Net price trends after rebates and discounts, with particular attention to employer channel pricing ²⁷
3. Manufacturing Capacity Utilization: Production scale-up progress and any indications of supply constraints
4. Competitive Pipeline Developments: Clinical readouts from Viking Therapeutics ^17,18, Structure Therapeutics ²⁵, Roche ²⁰, and oral GLP-1 candidates
5. Regulatory Communications: FDA advisory committee meetings, label updates, or safety communications related to bone health ¹⁰

Thesis Invalidation Triggers:

1. Market Share Loss Exceeding 15%: To next-generation competitors or oral formulations within 12-18 months of their launch
2. Net Price Erosion Exceeding 10% Annually: For consecutive years without offsetting volume acceleration
3. Major Safety Signal Requiring Black Box Warning: Or other significant label restriction impacting prescriber confidence
4. Manufacturing Capacity Gap Persisting Beyond 2026: Constraining revenue growth below $5 billion annually versus demand potential
5. Digital Platform Failure or Major Breach: Impairing distribution strategy and triggering regulatory intervention

Position Sizing Considerations

Given the binary characteristics and concentrated risk profile, position sizing should reflect:

• Maximum Position Size: 3-5% of concentrated portfolio, 1-3% of diversified portfolio
• Downside Protection: Options strategies or paired trades may be appropriate given valuation sensitivity to negative developments
• Rebalancing Triggers: Consider partial profit-taking at specific valuation thresholds (e.g., above $900 billion market capitalization) given risk-reward asymmetry at elevated levels

The manufacturing excellence that built Eli Lilly's historical success now faces its most rigorous test—scaling unprecedented demand while maintaining quality, navigating regulatory complexity, and defending against intensifying competition. The formulation is potent, but the excipients of market positioning must be precisely calibrated to achieve stable therapeutic effect on shareholder value.

Sources

1. SEC 4 for LLY (0001310215-26-000006) - 2026-03-17
2. SEC 4 for LLY (0001262388-26-000004) - 2026-02-18
3. The Risks of Buying GLP-1 Weight Loss Drugs Online Why physician supervision and trusted GLP-1 medic... - 2026-03-16
4. New paper in @bmj.com shows GLP-1 receptor agonists can tackle #SubstanceUseDisorder: i-base.info/h... - 2026-03-12
5. Almost 2,000 unauthorised weight loss drugs seized in MHRA raids. buff.ly/377TMQx #weightloss #we... - 2026-02-27
6. Dr Zubir Ahmed, Health Innovation and Patient Safety Minister, has urged people to not buy weight lo... - 2026-02-26
7. SEC 4 for LLY (0001752447-26-000004) - 2026-02-18
8. Die Jagd nach der «Abnehmspritze» in Fürth und Nürnberg: Rezeptfälscherin gefasst fuerthaktuell.de?... - 2026-02-18
9. What is the cost of institutional rot? Today, the FDA sent a warning letter to Novo Nordisk about s... - 2026-03-11
10. Study: #GLP1 drugs like #Ozempic may increase musculoskeletal risks. Over 5 years, osteoporosis risk... - 2026-03-09
11. Weight Loss Drugs. They've given people hope, but the scams are out there, and they’re sophisticated... - 2026-02-23
12. Weight Loss Drugs. They've given people hope, but the scams are out there, and they’re sophisticated... - 2026-02-22
13. Weight Loss Drugs. They've given people hope, but the scams are out there, and they’re sophisticated... - 2026-02-21
14. www.simpleonlinepharmacy.co.uk/online-docto... Discount code REF8E8MBA at checkout for prices below... - 2026-02-21
15. Weight Loss Drugs. They've given people hope, but the scams are out there, and they’re sophisticated... - 2026-02-20
16. Is Novo Nordisk or Eli Lilly the better place for manufacturing careers in Europe right now? - 2026-02-26
17. Novo just cut Wegovy/Ozempic prices up to 50% the day after CagriSema failed. - 2026-02-24
18. Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial - 2026-02-23
19. Lilly targets India as global export hub amid booming Mounjaro sales, executive says - 2026-02-17
20. A new weekly obesity injection shows promising results. 💉 Roche’s experimental drug Petrelintide hel... - 2026-03-06
21. Roche & Zealand Pharma report positive Phase 2 results for petrelintide, a novel long-acting amy... - 2026-03-10
22. Obesity Drugs Are Getting Easier and Cheaper to Find - 2026-03-12
23. Lilly Gets Lone Sell as HSBC Sees More Weight-Loss Drug Price Cuts - 2026-03-17
24. Eli Lilly says some Medicare plans may exceed $50 cap on weight-loss drugs - 2026-03-09
25. Structure Therapeutics’ Weight-Loss Pill Results Rival Novo, Lilly Treatments - 2026-03-16
26. Eli Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks - 2026-03-12
27. Lilly launches employer-connect platform to broaden weight-loss drug access - 2026-03-05